Clinical Trials
56 trialsNCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02285439 2025-10-07
Study of MEK162 for Children With Low-Grade Gliomas
Children's Hospital Los Angeles
Phase 1/2 Completed
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT03150862 2025-02-04
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
BeiGene
Phase 1/2 Completed
NCT03276676 2024-12-27
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
University of Utah
Phase 1/2 Terminated
NCT01217411 2024-11-19
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT01811498 2024-01-30
Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Northwell Health
Phase 1/2 Completed
NCT01128218 2023-11-30
A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors
Southern Illinois University
Phase 1/2 Completed
NCT03190967 2023-10-11
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01081223 2023-06-01
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
TVAX Biomedical
Phase 1/2 Completed
NCT02460874 2022-09-21
Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT00479765 2022-06-22
A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGelâ„¢ in Subjects With Recurrent Glioma
Boston Scientific Corporation
Phase 1/2 Terminated
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT01434602 2022-06-01
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT02154529 2022-04-27
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Kadmon Corporation, LLC
Phase 1/2 Terminated
NCT01677741 2021-11-24
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Novartis
Phase 1/2 Completed
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01120639 2021-08-06
Tx-Treatment
Stanford University
Phase 1/2 Completed
NCT02765165 2021-07-23
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
Phase 1/2 Terminated
NCT01051557 2021-07-19
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00293423 2021-05-13
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
University of California, San Francisco
Phase 1/2 Completed
NCT00924820 2020-12-31
A Pilot Study of Bevacizumab for Neoplastic Meningitis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00050986 2020-09-22
Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02855086 2020-03-31
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Terminated
NCT00049127 2019-10-21
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01806675 2019-10-03
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Phase 1/2 Completed
NCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00404248 2019-03-06
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01044966 2019-02-12
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
Medical University of South Carolina
Phase 1/2 Terminated
NCT01767415 2018-12-11
Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT00329719 2018-10-16
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01870726 2018-05-30
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Novartis
Phase 1/2 Terminated
NCT01648348 2018-05-23
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00045708 2017-10-18
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00045110 2017-08-17
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01465347 2017-07-14
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals Inc
Phase 1/2 Completed
NCT01026493 2017-07-02
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT01290263 2017-07-02
Amgen 386 for Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT00362817 2017-06-01
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00379080 2017-04-07
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00085540 2017-01-02
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01132664 2016-08-17
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Novartis
Phase 1/2 Terminated
NCT00301418 2016-02-10
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Northwell Health
Phase 1/2 Completed
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed